Miguel Prudêncio

Researcher. Biological Sciences. Malaria


“Novel 4(1H)-quinolonimine derivatives as antimalarial agents”. National Application No. 20111000058481, filed 26.07.2011

“Use of inhibitors of host kinases for the treatment of infectious diseases”, US provisional application NO. 61/110,217, filed 31.10.2008

“Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases” (WO/2007/101710), International Application No. PCT/EP2007/002110, National phases initialized in EU, US, CA and China in Oct. 2008

“Genetically modified rodent Plasmodium parasites as platforms for a whole-organism malaria vaccine” (WO 2013156949 A1, also published as CN104302313A, EP2838554A1, US20150071966)
Provisional application (Portugal) No. 20121000030819, filed 17.04.2012
PCT international application PCT/IB2013/053050, submitted 17.04.2013, published 24.10.2013.
Patent applications filed in Angola, Australia, Brazil, China, India, Japan, Mozambique, South Africa, United States, and European Patent (Euro-PCT), November 2014
Patent granted in India (07.08.2015), Mozambique (17.08.2015), South Africa (23.12.2015), Japan(2015), Australia (03.02.2017), USA (15.02.2017), China (20.11.2017), Europe (11.05.2018) and Hong-Kong (20.07.2018)

“Infected cell cultures”, European Patent Office application EP 17 160 277.4, filed on 10.03.2017. PCT application number PCT/EP2018/055717 (8 March 2018).

Novel spiro-lactam compounds, process and uses thereof“, Pub. No.: WO/2018/207165,
International Application No.: PCT/IB2018/053357,
International Filing Date: 14.05.2018,
Publication Date: 15.11.2018
Patent granted in USA (26.01.2023), USPTO issued on 06.06.2023